Performance of NTLA Intellia Therapeutics | -40.1% in 12m
Compare NTLA with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Intellia Therapeutics with its related Sector/Index XBI
Performance Duell NTLA vs XBI
| TimeFrame | NTLA | XBI |
|---|---|---|
| 1 Day | -0.19% | -0.02% |
| 1 Week | 5.27% | 4.06% |
| 1 Month | 20.0% | 8.15% |
| 3 Months | -5.66% | -0.60% |
| 6 Months | 0.58% | 32.05% |
| 12 Months | -40.1% | 8.91% |
| YTD | -15.1% | 2.62% |
| Rel. Perf. 1m | 0.88 | |
| Rel. Perf. 3m | -1.84 | |
| Rel. Perf. 6m | -2.68 | |
| Rel. Perf. 12m | -5.97 |
Is Intellia Therapeutics a good stock to buy?
No, based on ValueRay Fundamental Analyses, Intellia Therapeutics (NASDAQ:NTLA) is currently (May 2024)
a stock to sell. It has a ValueRay Fundamental Rating of -80.90 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NTLA as of May 2024 is 22.09. This means that NTLA is currently overvalued and has a potential downside of -15.59% (Sold with Premium).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NTLA as of May 2024 is 22.09. This means that NTLA is currently overvalued and has a potential downside of -15.59% (Sold with Premium).
Is NTLA a buy, sell or hold?
- Strong Buy: 17
- Buy: 6
- Hold: 5
- Sell: 0
- Strong Sell: 0
Values above 0%: NTLA is performing better - Values below 0%: NTLA is underperforming
Compare NTLA with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | 3.63% | 14.99% | -17.69% | -70.85% |
| US NASDAQ 100 | QQQ | 2.78% | 15.15% | -16.98% | -79.19% |
| US Dow Jones Industrial 30 | DIA | 3.95% | 14.26% | -14.54% | -63.29% |
| German DAX 40 | DBXD | 5.10% | 14.81% | -17.62% | -57.40% |
| UK FTSE 100 | ISFU | 3.21% | 9.51% | -17.62% | -54.81% |
| Shanghai Shenzhen CSI 300 | CSI 300 | 6.26% | 15.40% | -2.27% | -30.26% |
| Hongkong Hang Seng | HSI | 0.76% | -1.62% | -3.65% | -32.62% |
| Japan Nikkei 225 | EXX7 | 4.66% | 21.82% | -12.41% | -53.77% |
| India NIFTY 50 | INDA | 3.41% | 17.29% | -16.21% | -67.57% |
| Brasil Bovespa | EWZ | 5.74% | 14.60% | 3.09% | -53.86% |
NTLA Intellia Therapeutics vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | 4.29% | 16.94% | -17.71% | -79.03% |
| Consumer Discretionary | XLY | 5.98% | 17.32% | -6.93% | -61.65% |
| Consumer Staples | XLP | 3.69% | 12.75% | -13.79% | -45.90% |
| Energy | XLE | 6.01% | 20.78% | -14.33% | -65.97% |
| Financial | XLF | 4.05% | 13.45% | -21.58% | -74.86% |
| Health Care | XLV | 3.36% | 14.69% | -13.97% | -53.54% |
| Industrial | XLI | 5.59% | 17.16% | -19.74% | -70.50% |
| Materials | XLB | 5.66% | 17.10% | -14.67% | -60.49% |
| Real Estate | XLRE | 3.14% | 12.41% | -8.94% | -51.53% |
| Technology | XLK | 1.60% | 14.77% | -15.76% | -80.58% |
| Utilities | XLU | 3.95% | 4.84% | -17.84% | -52.29% |
| Aerospace & Defense | XAR | 4.87% | 12.46% | -15.33% | -67.06% |
| Biotech | XBI | 1.21% | 11.84% | -31.47% | -49.02% |
| Homebuilder | XHB | 5.80% | 14.61% | -31.14% | -93.16% |
| Retail | XRT | 2.90% | 12.16% | -24.60% | -69.83% |
Does Intellia Therapeutics outperform its market, is NTLA a Sector Leader?
No, over the last 12 months Intellia Therapeutics (NTLA) made -40.11%, while its related Sector, the SPDR S&P Biotech (XBI) made 8.91%.
Over the last 3 months NTLA made -5.66%, while XBI made -0.60%.
No, over the last 12 months Intellia Therapeutics (NTLA) made -40.11%, while its related Sector, the SPDR S&P Biotech (XBI) made 8.91%.
Over the last 3 months NTLA made -5.66%, while XBI made -0.60%.
| Period | NTLA | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 19.99% | 8.15% | 5.00% |
| 3 Months | -5.66% | -0.60% | 6.17% |
| 12 Months | -40.11% | 8.91% | 30.74% |